Jack Schuler Acquires 13,900 Shares of Biodesix (NASDAQ:BDSX) Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler purchased 13,900 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were purchased at an average price of $24.25 per share, for a total transaction of $337,075.00. Following the acquisition, the director owned 527,110 shares of the company’s stock, valued at approximately $12,782,417.50. The trade was a 2.71% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Biodesix Price Performance

Shares of BDSX opened at $23.79 on Friday. Biodesix, Inc. has a twelve month low of $5.26 and a twelve month high of $25.52. The company has a market capitalization of $250.98 million, a P/E ratio of -7.50 and a beta of 0.56. The firm has a 50 day moving average of $20.33 and a 200 day moving average of $16.13. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 5.12.

Biodesix (NASDAQ:BDSX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.19. Biodesix had a negative return on equity of 788.19% and a negative net margin of 26.97%.The business had revenue of $26.86 million for the quarter, compared to analysts’ expectations of $26.03 million. As a group, equities research analysts anticipate that Biodesix, Inc. will post -2.68 earnings per share for the current fiscal year.

Institutional Trading of Biodesix

Hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd increased its position in Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after buying an additional 102,494 shares in the last quarter. Millennium Management LLC bought a new position in shares of Biodesix during the 3rd quarter valued at approximately $113,000. Geode Capital Management LLC grew its stake in shares of Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock valued at $289,000 after acquiring an additional 2,235 shares during the period. Monashee Investment Management LLC increased its holdings in Biodesix by 12.3% in the 4th quarter. Monashee Investment Management LLC now owns 112,344 shares of the company’s stock worth $764,000 after acquiring an additional 12,348 shares in the last quarter. Finally, DRW Securities LLC bought a new stake in Biodesix during the 4th quarter worth approximately $105,000. Institutional investors own 20.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $27.00 target price (up from $26.00) on shares of Biodesix in a research report on Thursday, August 6th. Weiss Ratings upgraded shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 12th. Canaccord Genuity Group boosted their price objective on shares of Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a report on Monday. Finally, Roth Capital assumed coverage on shares of Biodesix in a research report on Wednesday, June 24th. They set a “buy” rating and a $32.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Biodesix presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.33.

More Biodesix News

Here are the key news stories impacting Biodesix this week:

• Positive Sentiment: Director Jack W. Schuler purchased an additional 15,000 shares for approximately $367,050 at an average price of $24.47 on August 12. Combined with purchases of 13,700 shares on August 11 and 13,900 shares on August 10, Schuler bought 42,600 shares for roughly $1.03 million over three sessions, increasing his direct ownership to 555,810 shares. The buying may signal confidence in Biodesix’s outlook. SEC insider transaction filing
• Positive Sentiment: Biodesix reported second-quarter adjusted performance that exceeded expectations: EPS was negative $0.71 versus the consensus estimate of negative $0.90, while revenue reached $26.86 million compared with an expected $26.03 million. The earnings call transcript provides additional discussion of the results and outlook. Biodesix Q2 2026 earnings call transcript
• Positive Sentiment: Analyst sentiment remains constructive. Canaccord Genuity raised its price target from $27 to $35 while maintaining a Buy rating, and HC Wainwright reiterated Buy with a $27 target. Roth Capital previously initiated coverage with a Buy rating and a $32 target. The reported consensus target is $31.33, above recent trading levels. Biodesix analyst price-target coverage
• Neutral Sentiment: Institutional ownership activity was mixed but included several new positions and additions, including AIGH Capital Management’s approximately $11.0 million stake and increased holdings by XTX Topco. Institutions own about 21% of BDSX.
• Negative Sentiment: Despite the revenue and EPS beat, Biodesix remains unprofitable, with a negative net margin and analysts forecasting approximately negative $2.68 EPS for the current year. Its debt-to-equity ratio of 5.12 also represents a financial risk, particularly after the stock’s substantial advance toward its 52-week high.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.